Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of a 10-Week High-Intensity Interval Training Programme on Biochemical and Hormonal Responses in Elite Female Futsal Players

19 août 2026 mis à jour par: Shimal Hamza Hamad, Soran University

Temporal Dynamics of Biochemical and Hormonal Responses to Interval Training in Elite Female Futsal Players: A 10-Week Longitudinal Analysis Across Menstrual Cycle Phases

This study aims to investigate the biochemical, hormonal, and physiological adaptations to a 10-week periodized high-intensity interval training (HIIT) programme in elite female futsal players. The study will examine changes in aerobic fitness, blood lactate kinetics, muscle damage biomarkers, inflammatory markers, and reproductive hormones throughout the intervention. In addition, the influence of menstrual cycle phases on these physiological responses will be evaluated to improve understanding of sex-specific training adaptations and recovery. The findings are expected to contribute to evidence-based, individualized training and recovery strategies for female futsal athletes.

Aperçu de l'étude

Description détaillée

Female futsal is a high-intensity intermittent team sport requiring substantial aerobic and anaerobic fitness. Despite increasing participation of women in competitive sports, limited evidence exists regarding the biochemical and hormonal adaptations to structured interval training, particularly across different menstrual cycle phases. This prospective longitudinal study will recruit 32 elite female futsal players who will participate in a supervised 10-week periodized HIIT programme consisting of lactate threshold training, anaerobic intensification, and sport-specific interval training. Physiological assessments will include VO₂max, lactate threshold, blood lactate kinetics, creatine kinase, interleukin-6, C-reactive protein, cortisol, and reproductive hormones. Menstrual cycle phases will be monitored using validated menstrual tracking methods and hormonal confirmation. Outcomes will be assessed repeatedly throughout the intervention to determine temporal adaptations and the influence of menstrual cycle phase on training responses and recovery. The results are expected to support individualized, evidence-based training prescription for female athletes.

Type d'étude

Interventionnel

Inscription (Réel)

32

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Erbil Governorate
      • Soran, Erbil Governorate, Irak, 44008
        • Soran Univeristy

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Female futsal players aged 18-30 years.
  • Regular menstrual cycles.
  • Participants willing to complete all scheduled testing sessions across the study period.
  • Participants able to safely participate in the prescribed physical-performance testing and training programme.

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Irregular menstrual cycles or diagnosed menstrual disorders.
  • Use of hormonal contraceptives or hormone therapy within the past 6 months.
  • Current musculoskeletal injury or any medical condition affecting physical performance.
  • Use of medications known to influence menstrual function, hormonal responses, or physical performance.
  • Use of performance-enhancing drugs or medications known to influence hormonal or biochemical responses.
  • History of endocrine, cardiovascular, or metabolic disorders.
  • Failure to complete all scheduled testing sessions.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Female Futsal Players
Female futsal players will undergo repeated standardized performance testing during different phases of the menstrual cycle. Assessments include agility, sprint speed, repeated sprint ability, explosive power, balance, and aerobic fitness. All participants receive the same testing protocol, and no therapeutic intervention is administered.
Female futsal players will undergo standardized physical performance testing during different phases of the menstrual cycle. Assessments include agility, sprint speed, repeated sprint ability, explosive power, balance, and aerobic fitness. The study involves repeated performance assessments only, and no drug, device, surgical procedure, or therapeutic intervention will be administered.
Autres noms:
  • Futsal Performance Testing

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mean Change from Baseline in Maximum Oxygen Uptake (VO₂max)
Délai: Baseline and Week 10
Maximum oxygen uptake (VO₂max) measured during a graded incremental treadmill exercise test with respiratory gas analysis. Unit of Measure: mL·kg-¹·min-¹.
Baseline and Week 10
Mean Change from Baseline in Velocity at VO₂max (vVO₂max)
Délai: Baseline and Week 10
Velocity at VO₂max (vVO₂max) measured during a graded incremental treadmill exercise test. Unit of Measure: km/h.
Baseline and Week 10
Mean Change from Baseline in Lactate Threshold Velocity
Délai: Baseline and Week 10
Lactate threshold velocity determined during incremental exercise testing. Lactate threshold velocity is defined as the running velocity corresponding to the lactate threshold. Unit of measure: km/h. Higher values indicate improved aerobic endurance.
Baseline and Week 10
Mean Change from Baseline in Resting Blood Lactate Concentration
Délai: Baseline and Week 10
Resting blood lactate concentration measured from venous blood samples collected under standardized resting conditions before exercise. Unit of Measure: mmol/L. Lower concentrations indicate improved metabolic efficiency.
Baseline and Week 10
Mean Change from Baseline in Lactate Clearance Rate
Délai: Baseline and Week 10
Lactate clearance rate calculated as the rate of decline in blood lactate concentration from serial post-exercise measurements obtained during standardized recovery. The calculated clearance rate is reported as one value in mmol/L/min. Higher clearance rates indicate improved metabolic recovery.
Baseline and Week 10

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Serum Creatine Kinase (CK) Concentration at Predefined Recovery Time Points
Délai: Baseline; immediately post-exercise; 24 hours; 48 hours; and 72 hours
Serum creatine kinase concentration measured at baseline and predefined post-exercise recovery time points. Repeated CK concentrations are evaluated across the predefined sampling time points. Unit of Measure: U/L.
Baseline; immediately post-exercise; 24 hours; 48 hours; and 72 hours
Interleukin-6 (IL-6)
Délai: Baseline; immediately post-exercise; and recovery period
Serum interleukin-6 concentration measured as an indicator of exercise-induced inflammatory response. Unit of Measure: pg/mL. Lower resting concentrations and appropriate acute exercise responses indicate improved inflammatory regulation.
Baseline; immediately post-exercise; and recovery period
Serum Cortisol
Délai: Baseline; menstrual phase-specific assessments; and Week 10
Serum cortisol concentration measured to evaluate physiological stress responses associated with high-intensity interval training. Unit of Measure: µg/dL.
Baseline; menstrual phase-specific assessments; and Week 10
Serum Estradiol
Délai: Phase-specific assessments during the intervention
Serum estradiol concentration measured to characterize hormonal status during different phases of the menstrual cycle. Unit of Measure: pg/mL.
Phase-specific assessments during the intervention
Serum Progesterone
Délai: Phase-specific assessments during the intervention
Serum progesterone concentration measured to confirm menstrual cycle phase and evaluate hormonal responses during the intervention. Unit of Measure: ng/mL.
Phase-specific assessments during the intervention

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Creatine Kinase (CK) Recovery Half-Life
Délai: Immediately post-exercise through 72 hours
Time required for serum creatine kinase concentration to decrease by 50% during the post-exercise recovery period. Unit of Measure: hours.
Immediately post-exercise through 72 hours
Area Under the Concentration-Time Curve of Serum Creatine Kinase (CK)
Délai: Immediately post-exercise through 72 hours
Area under the serum creatine kinase concentration-time curve calculated from serum CK concentrations measured during the post-exercise recovery period. Unit of Measure: U/L·h.
Immediately post-exercise through 72 hours

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

2 février 2026

Achèvement primaire (Réel)

1 juillet 2026

Achèvement de l'étude (Réel)

1 juillet 2026

Dates d'inscription aux études

Première soumission

31 juillet 2026

Première soumission répondant aux critères de contrôle qualité

14 août 2026

Première publication (Réel)

19 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • SORANU-HIIT-2026-001
  • Ethics Approval Number (Autre identifiant: Soran University Institutional Review Board)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

A decision regarding sharing de-identified individual participant data collected in this study has not yet been finalized. If data sharing is approved, only de-identified data may be considered for sharing after study completion, subject to institutional policies, ethical requirements, participant confidentiality, and applicable data-protection requirements.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner